Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo.

[1]  Yingyu Chen,et al.  Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo , 2010, Apoptosis.

[2]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[3]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[4]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[5]  H. Lenz,et al.  Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. , 2009, The oncologist.

[6]  R. Beart,et al.  Rates and predictors of chemotherapy use for stage III colon cancer , 2008, Cancer.

[7]  G. Jean,et al.  Epidermal Growth Factor Receptor Monoclonal Antibodies for the Treatment of Metastatic Colorectal Cancer , 2008, Pharmacotherapy.

[8]  B. Wolpin,et al.  Systemic treatment of colorectal cancer. , 2008, Gastroenterology.

[9]  A. Seifalian,et al.  Principles and applications of gene therapy in colon cancer. , 2008, Journal of gastrointestinal and liver diseases : JGLD.

[10]  K. Omura Advances in Chemotherapy against Advanced or Metastatic Colorectal Cancer , 2008, Digestion.

[11]  J. Rhee,et al.  Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. , 2007, World journal of gastroenterology.

[12]  Yan-rong Liu,et al.  Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. , 2006, Leukemia research.

[13]  Wei Guo,et al.  Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand–Armed Oncolytic Adenovirus , 2006, Clinical Cancer Research.

[14]  S. Howell,et al.  DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance , 2006, Molecular Cancer Therapeutics.

[15]  Ugo Pastorino,et al.  Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Kang,et al.  Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells , 2006, Apoptosis.

[17]  Y. Wang,et al.  Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression , 2006, Apoptosis.

[18]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[19]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[20]  W. Han,et al.  An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression , 2004, Journal of Cell Science.

[21]  D. Fraker,et al.  Combined 5-Fluorouracil/Systemic Interferon-β Gene Therapy Results in Long-Term Survival in Mice with Established Colorectal Liver Metastases , 2004, Clinical Cancer Research.

[22]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[23]  Dalong Ma,et al.  Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. , 2002, Life sciences.

[24]  E. Jeffes,et al.  Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9 gliomas. , 2002, Blood.

[25]  H. Kawasaki,et al.  Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. , 2002, Carcinogenesis.

[26]  G. Fu,et al.  Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  L. Young,et al.  High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  N. Abraham,et al.  Synergetic Effects of Retrovirus IFN-alpha Gene Transfer and 5-FU on Apoptosis of Colon Cancer Cells , 1999, Acta Haematologica.

[30]  H. Liu,et al.  TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. , 1999, Biochemical and biophysical research communications.

[31]  C. Borner,et al.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.

[32]  L. Milas,et al.  Kinetics of cisplatin‐induced apoptosis in murine mammary and ovarian adenocarcinomas , 1995, International journal of cancer.

[33]  M. Gurney,et al.  Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. , 1994, The American journal of pathology.

[34]  C. Sorenson,et al.  Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. , 1990, Journal of the National Cancer Institute.

[35]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[36]  F. Gao,et al.  Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. , 2008, Oncology reports.

[37]  Seth M. Cohen,et al.  Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.

[38]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[39]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.